Pharmacogenetic factors affecting β-blocker metabolism and response.

Published in: Expert opinion on drug metabolism & toxicology (2020)

Substantial data suggest that specific ADRB1 and GRK5 genotypes are associated with improved β-blocker efficacy and have potential for use to guide therapy decisions in the clinical setting. While the data do not justify ordering a CYP2D6 pharmacogenetic test, if CYP2D6 genotype is available in the electronic health record, there may be clinical utility for understanding dosing of β-blockers.

Keyphrases

electronic health record
angiotensin converting enzyme
clinical decision support
adverse drug
angiotensin ii
big data
stem cells
machine learning
artificial intelligence
climate change
deep learning